{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:34:16Z","timestamp":1722472456633},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:00:00Z","timestamp":1722297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:00:00Z","timestamp":1722297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The 5-2-1 criteria was developed to facilitate the identification and referral of patients with Parkinson\u2019s Disease (PD) inadequately controlled by oral medications. The criterion was not developed to screen patients with PD for device-aided therapy eligibility. The robust design and validation of the 5-2-1 criteria minimizes over or inappropriate referrals, and supports physicians in the timely identification of patients with PD who may warrant further evaluation for treatment optimization. This response letter clarifies concerns raised by Moes et al.<\/jats:p>","DOI":"10.1186\/s12883-024-03691-3","type":"journal-article","created":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T16:02:29Z","timestamp":1722355349000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Response to letter to the editor regarding \u201cDoes the 5-2-1 criteria identify patients with advanced Parkinson\u2019s disease? Real-world screening accuracy and burden of 5-2-1-positive patients in 7 countries\u201d"],"prefix":"10.1186","volume":"24","author":[{"given":"Angelo","family":"Antonini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. Ray","family":"Chaudhuri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josefa","family":"Domingos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joohi","family":"Jimenez-Shahed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack","family":"Wright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Connie H.","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Alobaidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Bergmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koray","family":"Onuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Harmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene A.","family":"Malaty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,30]]},"reference":[{"issue":"1","key":"3691_CR1","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12883-022-02560-1","volume":"22","author":"IA Malaty","year":"2022","unstructured":"Malaty IA, Martinez-Martin P, Chaudhuri KR, Odin P, Skorvanek M, Jimenez-Shahed J, et al. Does the 5-2-1 criteria identify patients with advanced Parkinson\u2019s disease? Real-world screening accuracy and burden of 5-2-1-positive patients in 7 countries. BMC Neurol. 2022;22(1):35.","journal-title":"BMC Neurol"},{"issue":"11","key":"3691_CR2","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1185\/03007990802457040","volume":"24","author":"P Anderson","year":"2008","unstructured":"Anderson P, Benford M, Harris N, Karavali M, Piercy J. Real-world physician and patient behaviour across countries: Disease-Specific programmes - a means to understand. Curr Med Res Opin. 2008;24(11):3063\u201372.","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"3691_CR3","doi-asserted-by":"publisher","first-page":"e010352","DOI":"10.1136\/bmjopen-2015-010352","volume":"6","author":"SM Babineaux","year":"2016","unstructured":"Babineaux SM, Curtis B, Holbrook T, Milligan G, Piercy J. Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the Disease Specific Programme. BMJ Open. 2016;6(8):e010352.","journal-title":"BMJ Open"},{"key":"3691_CR4","doi-asserted-by":"publisher","first-page":"371","DOI":"10.2147\/DMSO.S120101","volume":"9","author":"V Higgins","year":"2016","unstructured":"Higgins V, Piercy J, Roughley A, Milligan G, Leith A, Siddall J, et al. Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015. Diabetes Metab Syndr Obes. 2016;9:371\u201380.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"12","key":"3691_CR5","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1080\/03007995.2018.1502165","volume":"34","author":"A Antonini","year":"2018","unstructured":"Antonini A, Stoessl AJ, Kleinman LS, Skalicky AM, Marshall TS, Sail KR, et al. Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson\u2019s disease: a multi-country Delphi-panel approach. Curr Med Res Opin. 2018;34(12):2063\u201373.","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"3691_CR6","first-page":"749","volume":"94","author":"W Muangpaisan","year":"2011","unstructured":"Muangpaisan W, Mathews A, Hori H, Seidel D. A systematic review of the worldwide prevalence and incidence of Parkinson\u2019s disease. J Med Assoc Thai. 2011;94(6):749\u201355.","journal-title":"J Med Assoc Thai"},{"issue":"7","key":"3691_CR7","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1007\/s00134-003-1761-8","volume":"29","author":"JE Fischer","year":"2003","unstructured":"Fischer JE, Bachmann LM, Jaeschke R. A readers\u2019 guide to the interpretation of diagnostic test properties: clinical example of sepsis. Intensive Care Med. 2003;29(7):1043\u201351.","journal-title":"Intensive Care Med"},{"issue":"1\u20132","key":"3691_CR8","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S0167-5877(00)00115-X","volume":"45","author":"M Greiner","year":"2000","unstructured":"Greiner M, Pfeiffer D, Smith RD. Principles and practical application of the receiver-operating characteristic analysis for diagnostic tests. Prev Vet Med. 2000;45(1\u20132):23\u201341.","journal-title":"Prev Vet Med"},{"issue":"4857","key":"3691_CR9","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1126\/science.3287615","volume":"240","author":"JA Swets","year":"1988","unstructured":"Swets JA. Measuring the accuracy of diagnostic systems. Science. 1988;240(4857):1285\u201393.","journal-title":"Science"},{"key":"3691_CR10","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.parkreldis.2021.10.009","volume":"92","author":"A Antonini","year":"2021","unstructured":"Antonini A, Odin P, Schmidt P, Cubillos F, Standaert DG, Henriksen T, et al. Validation and clinical value of the MANAGE-PD tool: a clinician-reported tool to identify Parkinson\u2019s disease patients inadequately controlled on oral medications. Parkinsonism Relat Disord. 2021;92:59\u201366.","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"3691_CR11","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/mdc3.13962","volume":"11","author":"D Brinker","year":"2024","unstructured":"Brinker D, Smilowska K, Paschen S, Antonini A, Moro E, Deuschl G. How to use the New European Academy of Neurology\/Movement Disorder Society European Section Guideline for Invasive Therapies in Parkinson\u2019s Disease. Mov Disord Clin Pract. 2024;11(3):209\u201319. https:\/\/doi.org\/10.1002\/mdc3.13962.","journal-title":"Mov Disord Clin Pract"},{"issue":"7","key":"3691_CR12","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1002\/mds.29066","volume":"37","author":"G Deuschl","year":"2022","unstructured":"Deuschl G, Antonini A, Costa J, et al. European Academy of Neurology\/Movement Disorder Society-European Section Guideline on the treatment of Parkinson\u2019s Disease: I. Invasive therapies. Mov Disord. 2022;37(7):1360\u201374. https:\/\/doi.org\/10.1002\/mds.29066.","journal-title":"Mov Disord"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-024-03691-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-024-03691-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-024-03691-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T11:09:51Z","timestamp":1722424191000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-024-03691-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,30]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3691"],"URL":"https:\/\/doi.org\/10.1186\/s12883-024-03691-3","relation":{},"ISSN":["1471-2377"],"issn-type":[{"type":"electronic","value":"1471-2377"}],"subject":[],"published":{"date-parts":[[2024,7,30]]},"assertion":[{"value":"22 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Disease Specific Programme was conducted in accordance with the European Pharmaceutical Market Research Association (EphMRA) Code of Conduct. The study protocol (reference number AG8689) was submitted to the Western Institutional Review Board, and an ethics waiver was provided as it was determined that ethics approval was not required for this study. All data were collected following procedures with ethics committee approval, and data were fully de identified prior to receipt by Adelphi Real World. The respondents provided informed consent for use of their anonymized and aggregated data for research and publication in scientific journals. All data, i.e. methodology, materials, data, and data analysis, that support the findings of this survey are the intellectual property of Adelphi Real World. As such no administrative permissions were required to access and use the data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"IAM has participated in research funded by AbbVie, Emalex, Neuroderm, Revance, and Sage but has no owner interest in any pharmaceutical company. She has consulted for Abbvie and received royalties from Robert Rose Publishers; KRC has received educational funding from UCB, and honoraria for sponsored symposiums from UCB, AbbVie, Britannia, US Worldmeds, Otsuka, Medtronic, Zambon and acted as a consultant for AbbVie, UCB, Britannia, Medtronic and Mundipharama; JJ-S has received consulting fees from Teva, Nuvelution, Bracket, Amneal, Revance, AbbVie, CNS Ratings, St. Jude Medical, Medtronic and research funding from Impax; JD declares no relevant conflict of interest to present study; CHY, AlA, KO, LB, and LH are employees of AbbVie and may own stocks\/shares in the company; JW is an employee of Adelphi Real World, a consulting company that was hired by AbbVie to perform analyses on the Adelphi Disease Specific Programme database; AnA has received compensation for consultancy and speaker related activities from UCB, Boehringer Ingelheim, Britannia, AbbVie, Kyowa Kirin, Zambon, Bial, Neuroderm, Theravance Biopharma, Roche; he receives research support from Chiesi Pharmaceuticals, Lundbeck, Horizon 2020 - Grant 825785, Horizon2020 Grant 101016902, Ministry of Education University and Research (MIUR) Grant ARS01_01081, Cariparo Foundation. He serves as consultant for Boehringer Ingelheim for legal cases on pathological gambling.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"266"}}